Study of a drug to prevent low white blood cells after chemo-immunotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have stage IV small cell lung cancer, stage IV non-small cell lung cancer, or stage IV esophageal cancer (or certain advanced lung tumors that can't be treated with radiation)
- You have not had chemotherapy for advanced cancer before, or if you did, it was more than 6 months ago
- You are about to receive chemotherapy that has a high or medium risk of causing a fever from low white blood cells
- You are in good general health (able to do daily activities, ECOG 0 or 1)
- Your blood counts and organ function meet certain minimum levels (e.g., adequate white blood cells, kidney and liver function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests a new way to give a medicine that helps your body make white blood cells after chemotherapy for breast cancer. It may help prevent serious infections.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.